Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Boehringer Ingelheim Pharmaceuticals, Inc.

US Class II Ongoing · initiated 2026-06-12

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a dif…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

BioMed Laboratories, LLC.

US Class II Ongoing · initiated 2026-06-11

Failed Impurities/Degradation Specifications; Formaldehyde levels exceeded specification.

ACCORD BIOPHARMA INC

US Class II Ongoing · initiated 2026-06-10

Lack of assurance of Sterility:

Nicotine Pouch

Canada Type II Ongoing · initiated 2026-06-10

Unauthorized product. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any heal…

Asclemed USA Inc.

US Class II Ongoing · initiated 2026-06-08

Lack of Assurance of Sterility

ACCORD HEALTHCARE, INC.

US Class II Ongoing · initiated 2026-06-08

Subpotent Drug

Asclemed USA Inc.

US Class II Ongoing · initiated 2026-06-08

Lack of Assurance of Sterility

Sodium chloride injection; Sodium chloride Irrigation; (20 mmol/L) Potassium chloride in 5% Dextrose and 0.9% Sodium chloride injection; Lactated Ringer's injection

Canada Type III Ongoing · initiated 2026-06-08

Packaging. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns…

PMS-Fluconazole 50 mg tablets

Canada Type III Ongoing · initiated 2026-06-08

Packaging. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns…

ONESOURCE SPECIALTY PHARMA LIMITED

US Class II Ongoing · initiated 2026-06-07

Failed Impurities/Degradation Specifications

Inventia Healthcare Limited

US Class II Ongoing · initiated 2026-06-05

Failed Dissolution Specifications

Haleon US Holdings LLC

US Class I Ongoing · initiated 2026-06-04

Chemical Contamination: contamination with a diluted propylene glycol-based coolant from a machine leakage during the packaging process.

Breckenridge Pharmaceutical, Inc.

US Class II Ongoing · initiated 2026-06-04

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Breckenridge Pharmaceutical, Inc.

US Class II Ongoing · initiated 2026-06-04

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Annora Pharma Private Limited

US Class II Ongoing · initiated 2026-06-04

Presence of a Foreign Tablets: Complaint received, possible mix-up of Selexipag 1000 mcg tablet in a bottle of Lacosamide Tablets USP, 100mg.